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Abstract
Introduction: The difficulties in the management of the blunt chest wall trauma patient in the Emergency Department due
to the development of late complications are well recognised in the literature. Pre-injury anti-platelet therapy has been
previously investigated as a risk factor for poor outcomes following traumatic head injury, but not in the blunt chest wall
trauma patient cohort. The aim of this study was to investigate pre-injury anti-platelet therapy as a risk factor for the
development of complications in the recovery phase following blunt chest wall trauma.
Methods: A retrospective study was completed in which the medical notes were analysed of all blunt chest wall trauma
patients presenting to a large trauma centre in Wales in 2012 and 2013. Using univariate and multivariable logistic
regression analysis, pre-injury platelet therapy was investigated as a risk factor for the development of complications
following blunt chest wall trauma. Previously identified risk factors were included in the analysis to address the influence of
confounding.
Results: A total of 1303 isolated blunt chest wall trauma patients presented to the ED in Morriston Hospital in 2012 and
2013 with complications recorded in 144 patients (11%). On multi-variable analysis, pre-injury anti-platelet therapy was
found to be a significant risk factor for the development of complications following isolated blunt chest wall trauma (odds
ratio: 16.9; 95% confidence intervals: 8.2–35.2). As in previous studies patient age, number of rib fractures, chronic lung
disease and pre-injury anti-coagulant use were also found to be significant risk factors.
Conclusions: Pre-injury anti-platelet therapy is being increasingly used as a first line treatment for a number of conditions
and there is a concurrent increase in trauma in the elderly population. Pre-injury anti-platelet therapy should be considered
as a risk factor for the development of complications by clinicians managing blunt chest wall trauma.
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Introduction
The use of anti-platelet therapy has increased over the last
decade as a result of research which has reported their
effectiveness in preventing cardiovascular events in high risk
populations. [1] A simultaneous change has also occurred in
trauma epidemiology, with an ever-increasing elderly trauma
population. [2] Anti-platelet therapy is more common in the
elderly age group primarily due to the higher incidence of co-
morbidities. [3] The therapeutic mechanisms of anti-platelet
agents include inhibition of platelet aggregation which results in
the impairment of normal haemostasis. [4] Research has
demonstrated that this impairment can lead to increased incidence
of post-traumatic intracranial haemorrhage, potentially increasing
morbidity and mortality in traumatic brain injury patients. [1,3,4]
Limited research has been completed to date which investigates
whether outcomes are also adversely affected by pre-injury anti-
platelet therapy in the isolated blunt chest wall trauma population.
Blunt chest wall trauma accounts for over 15% of all trauma
admissions to Emergency Departments worldwide. [5] Reported
mortality is as high as 22% in this patient cohort. [6] The
difficulties in the management of the blunt chest wall trauma
patient are becoming increasingly well recognised in the literature.
[7,8] The blunt chest wall trauma patient commonly presents to
the Emergency Department (ED) initially with no respiratory
difficulties, but can develop respiratory complications approxi-
mately 48 to 72 hours later. [9,10] Clinical symptoms are not
considered an accurate predictor of outcome following non-life
threatening blunt chest wall trauma. [11] A number of well-
documented risk factors for morbidity and mortality exist for blunt
chest wall trauma including patient age, pre-existing disease,
number of ribs fractured, pre-injury anticoagulant use and the on-
set of pneumonia during the recovery phase. [12,13]The aim
of this study was to investigate whether the use of pre-injury
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anti-platelets is a risk factor for the development of complications
in blunt chest wall trauma patients.
Methodology
Setting
A retrospective study design was used in order to examine the
medical notes of all blunt chest wall trauma patients who presented
to the ED of a large regional trauma centre in South Wales
(Morriston Hospital) in 2012 and 2013. Morriston hospital has
approximately 90,000 presentations to the ED per year and serves
a population of 450,000 people. Those patients coded as ‘blunt
chest trauma’ or ‘rib fractures’ were identified using the hospital
database. Patients with any significant concurrent injuries were
excluded to reduce the effect of confounding.
Sample
We wished to include sufficient patients that we could present
the unadjusted and adjusted odds ratios and 95% confidence
intervals for the risk factors for the development of complications
following blunt chest wall trauma. Peduzzi et al (1995) suggested
that the number of patients needed to ensure sufficient power in a
retrospective cohort study is equivalent to ten events per variable
(EPV) being investigated. [14] In this study we set out to
investigate six variables or risk factors based on previous research
therefore a minimum of 60 events (on-set of complications
following blunt chest wall trauma) were required.
Data Collection
The medical notes were reviewed following guidelines suggested
in a study by Gilbert et al (1996). [15] The ED medical notes of all
patients aged 16 years and over presenting to the ED of Morriston
Hospital in 2012 and 2013 were examined and data recorded on a
pre-designed database. A validation check was completed in which
an additional researcher checked the accuracy of data input for
10% of all patients, in order to reduce information bias. If a
patient’s notes had missing or incomplete data for the variables
under investigation, they were still included in the database.
The dataset included demographic variables such as age, gender
and injury mechanism. The independent variables examined were
defined a priori and consisted of the risk factors for mortality and
morbidity highlighted previously in the literature. [13] These
included patient age, chronic lung disease, number of rib fractures
and pre-injury anticoagulant use. Pre-injury anti-platelet use was
also investigated as the primary variable of interest in this study.
The outcome measure investigated was the development of
complications in the recovery phase following blunt chest wall
trauma. To ensure confidentiality, patients’ names were not
recorded during the data collection period. The dataset was also
stored on a hospital encrypted computer to ensure data security
(Safe-end protector encryption).
Ethics Statement
The South West Wales Research and Ethics Committee
confirmed that ethical approval was not required for this study
and also waived the need to obtain written informed consent from
the patients. All patient information was anonymised and de-
identified prior to analysis.
Definition of Variables
The patient’s age, chronic lung disease including; chronic
obstructive pulmonary disease or bronchiectasis, pre-injury anti-
coagulant use (all anti-coagulants and any dose included), pre-
injury anti-platelet use (all anti-platelets and any dose included)
were all identified from the medical notes. The number of rib
fractures was determined by the clinical notes however in the cases
where the number of rib fractures could not be determined using
the clinical records, then the x-ray report (IMPAX software) was
reviewed by the investigators.
The development of complications during the recovery phase
following blunt chest wall trauma was the composite outcome
measure investigated in this study. Data collection for this outcome
was completed from the time the patient presented to the ED
through to discharge from hospital. Patients were reported to have
developed complications if one or more of the following were
documented in their medical records; in-hospital mortality,
morbidity including all pulmonary complications (chest infection,
pneumonia, haemothorax, pneumothorax, pleural effusion, or
empyema), ICU admission, an unplanned representation to the
ED, or a prolonged length of stay as defined as a total hospital stay
of seven or more days.
Data Analysis
Baseline characteristics were presented as median and inter-
quartile range (due to non-normal distributions) for the continuous
variables and numbers and percentages for categorical variables.
Differences between the baseline characteristics were analysed
using Mann Whitney U test (continuous variables) and Fisher’s
Exact test (categorical variables). Odds ratios and 95% confidence
intervals were presented from the univariable analysis. All
significant prognostic variables at 5% significance on the
univariable analysis were included in final analysis. Multivariable
logistic regression analysis using fractional polynomials (to assess
linearity of the continuous variables) was used to identify
significant predictors using the Likelihood test statistic. There
was less than 2% missing data therefore we used a simple
imputation of the mean method to avoid exclusion of patients from
the final analysis. [16] Stata Release 13 was used for all data
analysis.
Results
A total of 1303 isolated blunt chest wall trauma patients
presented to the ED in Morriston Hospital in 2012 and 2013 with
complications recorded in 144 patients (11%). Data including
demographics, independent and dependent variables were record-
ed for each of the patients. With the exception of recording of
eleven patients’ oxygen saturations, there were no missing
variables in the dataset. Pre-injury anti-platelet therapy was
recorded in 116 patients (9%) of the entire cohort. Aspirin was
most commonly used antiplatelet medication (104 patients, 8%),
followed by NSAIDs (six patients, 0.5%), clopidogrel (five patients,
0.4%) and combined aspirin and clopidogrel (one patient, 0.08%).
Warfarin was the most commonly used anti-coagulant (n = 35,
3%) followed by Dabigatran (two patients, 0.2%). Haemorrhagic
events (haemothorax) were recorded in 36 out of 144 (25%)
patients who developed complications. Table 1 highlights the
demographic data for each of the patients. Patients’ gender, injury
mechanism and complication rate are presented.
Table 2 highlights the results of each risk factor investigated
using univariate analysis. The unadjusted odds ratios and their
95% confidence intervals are presented for each categorical risk
factor investigated. The risk factors for development of complica-
tions following blunt chest wall trauma were patient age, number
of rib fractures, chronic lung disease, pre-injury anti-coagulant use
and pre-injury anti-platelet use.
No significant association was found between the variables pre-
injury anti-coagulants and pre-injury anti-platelets. The only
Antiplatelet Therapy and Blunt Chest Wall Trauma
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significant associations found were between anticoagulant use and
chronic lung disease (p = 0.001), and antiplatelet use and chronic
lung disease (p,0.001). However this association led to no
significant interactions in the model on multivariate analysis
(p = 0.77 and p= 0.78 respectively). Results of the multivariable
logistic regression analysis are outlined in Table 3 and the adjusted
odds ratios and the 95% confidence intervals presented. Results
highlight that the significant risk factors for the development of
complications following blunt chest wall trauma were age, number
of rib fractures, chronic lung disease, pre-injury anticoagulant use
and pre-injury anti-platelet use. The final model omnibus test was
p,0.001 indicating an accurate overall model for predicting
complications with the predictors investigated.
Discussion
As no current guidelines exist for the management of this
patient group, recognition of the high risk patient in the ED is not
always straightforward due to the nature of the injury and its
recovery phase. The blunt chest wall trauma patient who walks
into the ED with no immediate life-threatening injury will
commonly develop complications up to 72 hours or more post
injury, which may also prove life-threatening. [9,10] An under-
standing of the risk factors for development of late complications in
blunt chest wall trauma patient could assist in the accurate risk
stratification of this patient group in the ED and thus improve
outcomes. A number of risk factors for the development of
complications following blunt chest trauma have been investigated
in this single centre retrospective study including patient age,
number of rib fractures, chronic lung disease and pre-injury anti-
coagulant use. These results support the reported findings of
previous studies.[9,12,13,17–19] The interesting finding in this
study however is that pre-injury anti-platelet use is also a
significant risk factor for complications following blunt chest wall
trauma.
The antithrombotic action of aspirin (acetylsalicylic acid) is due
to inhibition of platelet function by acetylation of the platelet
cyclooxygenase (COX) at the functionally important amino acid
serine529. This results in an irreversible inhibition of platelet-
dependent thromboxane formation. [20,21] It is well-recognised
that aspirin is considered the gold standard antiplatelet agent for
prevention of arterial thromboses. [21] The optimum dose of
aspirin as an antithrombotic drug can differ in different organ
circulations. While 100 mg/day is sufficient for prevention of
thrombus formation in the coronary circulation, higher doses may
be required for the prevention of vascular events in the cerebral
and peripheral circulation. [20] Any effective dose of aspirin
however is associated with an increased risk of bleeding, especially
in the trauma population [20].
Over the last decade, the use of antiplatelet therapy has
increased considerably, as a result of national and international
guidelines promoting their widespread in high-risk populations
and particularly in the elderly. [3] The epidemiology of the trauma
population has concurrently changed, with an ever increasing
prevalence of older age-groups. [3] It is in this increasing elderly
population where antiplatelet drug use is more prevalent. As a
result of this increased use of anti-platelet therapy as the
population ages, it is vital that trauma clinicians understand the
risks involved with their use. Pre-injury anti-platelet use has been
increasingly investigated as a risk factor for various poor outcomes
in traumatic head injuries. [1,3,4] A number of studies have
concluded that anti-platelet therapy is a risk factor for both short-
term and long-term unfavourable outcomes in subjects with head
injury, with increased risk of death, permanent vegetative state and
severe disability. [3] A further difficulty currently facing trauma
Table 1. Patients’ demographics, injury mechanisms and
complication rate.
Total patients (n =1303)
Age (mean/SD) 50 (±21)
Gender
Male 761 (58%)
Female 542 (42%)
Injury Mechanism
Fall 907 (70%)
Road traffic accident 182 (14%)
Assault 89 (7%)
Sporting injury 105 (8%)
Other 20 (2%)
Complication 144 (11%)
Mortality 5 (0.4%)
Morbidity 56 (4%)
ICU admission 16 (1%)
Unplanned representation to the ED 22 (2%)
Prolonged length of stay 57 (4%)
n: number, SD: standard deviation, ICU: Intensive Care Unit, ED: Emergency
Department.
doi:10.1371/journal.pone.0091284.t001
Table 2. Results of univariate analysis: Risk factors for complications in blunt chest wall trauma.
Complicationsn =144
(11%)
No complications n=1159
(89%)
Categorical variables n (%) n (%) p value Unadjusted OR (95%CI)
Chronic lung disease 17 27 p,0.001 5.6 (3.0–10.6)
Pre-injury anti-coagulant use 21 16 p,0.001 12.2 (6.2–24.0)
Pre-injury anti-platelet use 62 54 p,0.001 15.5 (10.1–23.7)
Continuous variables Median (IQR) Median (IQR) p value
Age 70 (26) 46 (31) p,0.001
Number of rib fractures 2 (2) 0 (0) p,0.001
OR: odds ratio; CI: confidence interval. Fisher Exact tests were used to analyse categorical variables and Mann-Whitney test for the continuous variables.
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clinicians is that limited research exists that addresses the efficacy
or utility of reversing pre-injury anti-platelets therapy in traumatic
head injury. [1].
Another difficulty facing emergency physicians in the manage-
ment of trauma patients using pre-injury anti-platelets is the
variation between patients in their response to the medication.
Platelet function tests can be carried out on trauma patients in
order to assess number and size of platelets and also platelet
haemostatic function. The type of tests completed, specifically
either global screening tests or specific assays will depend on the
testing equipment available at that emergency department. The
decision as to whether the blunt poly-trauma patient requires
platelet transfusion therefore is dependent on a number of factors.
In isolated blunt chest trauma however platelet function may not
routinely be considered by the emergency physician even though
delayed haemothorax is not an uncommon entity in this patient
group. [10] It could be suggested that tests for platelet function
may be an important consideration for the emergency physician
managing the isolated blunt chest trauma patient however further
research is required to support this suggestion.
To date, no research exists investigating the effect of pre-injury
anti-platelet use in blunt chest trauma. Pulmonary contusion
occurs in 25–35% of all blunt chest traumas and is defined as an
injury to the alveolar capillaries, in the absence of a lung
laceration. [22] This results in accumulation of blood and other
fluids within the lung tissue which subsequently interferes with gas
exchange leading to hypoxia. [22] If blood and plasma are leaked
into the alveoli in rib fractures patients, it possible that this
pathophysiological process is exacerbated in patients receiving pre-
injury anti-platelet therapy. This variable has not been investigat-
ed to date as a risk factor for poor outcomes following blunt chest
wall trauma. In one previous study, pre-injury anti-platelet therapy
was reported to reduce the incidence of acute lung injury in a
medical ICU population, of which there were 24 poly-trauma
patients in the study cohort and only eight of these were using pre-
injury anti-platelets. [23] The authors of this study also do not
state whether these trauma patients had sustained head injuries
and therefore comparison between the studies is not possible [23].
In a recent study by Harr et al (2013), the use of pre-injury anti-
platelet therapy was reported to be associated with a decreased risk
of lung dysfunction in high risk blunt trauma patients who receive
blood transfusions. [24] Neal et al (2014) reported similar findings,
concluding that NSAID use before admission for severe injury is
associated with a reduced incidence of trauma-induced coagulop-
athy. [25] The results of this study do not support the findings of
Harr et al (2013) and Neal et al (2014) however the study
populations are have distinct differences. The patients included in
the study by Harr et al [2013] were all severely injured poly-
trauma patients who had all received blood transfusions and were
at considered at risk of multi-organ failure. [24] Similarly the poly-
trauma patients in the study by Neal et al (2014) all presented with
haemorrhagic shock following blunt injury. [25] In contrast, the
patients in our study were isolated blunt chest trauma patients who
were not in haemorrhagic shock and had not received blood
transfusions. Patients with concurrent injuries were excluded.
Pathophysiological mechanisms of isolated blunt chest trauma are
evidently very different to those of major poly-trauma. It is not
possible therefore to compare these studies findings due to the
heterogeneity in study populations.
Study Limitations
One potential limitation of the study is that polytrauma patients
were excluded so the results are only generalisable to isolated blunt
chest wall trauma patients. The number of haemorrhagic
complications was recorded on data collection however data were
not collected regarding thromboembolic events in the study
population and this information may have been beneficial to the
clinician. Similarly the very small number of patients taking anti-
platelet therapy other than aspirin precludes analysis into which
therapy is most associated with specific complications. Lack of data
regarding platelet function in individual patients and platelet
transfusions may have influenced the study results.
As a result of the study design and the inherent nature of
patients, a number of the independent variables investigated were
potentially interdependent and an increase in one variable
inadvertently leads to an increase in another. Multivariable
logistic regression with backward elimination techniques was used
in an attempt to address this issue of collinearity. It is also possible
that a confounding variable that influences the results was not
considered in the data collection or analysis. It could therefore be
suggested that the discovered association between anti-platelet
therapy and chest wall complications is the result of both risk
factor and outcome being related to common underlying
unmeasured pathologies of some kind. In prognostic clinical
research however this is difficult to overcome due to the nature of
the study population and therefore the results of the study should
be interpreted with this in mind.
The use of the database to identify the patients for inclusion in
this study may have resulted in a degree of selection bias. Errors
may have occurred in the collation of the list of patients from the
hospital database and similarly by the doctors completing the
coding form in the ED. Similarly, as the data were being collected
for each of the patients from their ED medical notes, reliance was
placed on the information being both accurately and legibly
documented. This may have led to some error in data collection
and should be considered when interpreting the study results. The
most appropriate method of overcoming a number of the study
limitations is to complete a prospective study.
Table 3. Risk factors and their adjusted odds ratios for the development of complications following blunt chest wall trauma (all
p,0.05).
Risk factor Complications Adjusted OR (95%CI) p value
Age 1.0 (1.0–1.0) p = 0.017
Chronic lung disease 5.6 (2.2–14.6) p,0.001
Number of rib fractures 5.0 (3.9–6.5) p,0.001
Pre-injury anti-coagulant use 22.0 (8.3–58.2) p,0.001
Pre-injury anti-platelet use 17.8 (8.6–37.0) p,0.001
OR: odds ratios; CI: confidence intervals. OR for age is per one year increase. OR for number of rib fractures is per one fracture increase.
doi:10.1371/journal.pone.0091284.t003
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Conclusions
This study has highlighted a number of well-recognised risk
factors for the development of complications following blunt chest
wall trauma. These included patient age, number of rib fractures,
chronic lung disease and pre-injury anti-coagulant use. This is the
first study in which pre-injury anti-platelet use has been reported
as a risk factor for complications following isolated blunt chest wall
trauma. Pathophysiological mechanisms differ substantially be-
tween blunt poly-trauma patients suffering trauma-induced
coagulopathy and isolated blunt chest trauma patients and as a
result, comparisons between such studies are not appropriate. The
results of this study are therefore distinctive from any previous
research and should be considered by emergency physicians
managing isolated blunt chest trauma.
Anti-platelet therapy is now a well-recognised risk factor for
potential poor outcomes following severe traumatic head injuries
and trauma clinicians are becoming increasingly aware of its
negative impact in the elderly trauma patient. Despite the
limitations associated with a single centre retrospective study, this
results of this study have highlighted an important clinical finding
that trauma clinicians should consider when managing the blunt
chest wall trauma patient in the ED. A prospective multi-centre
study is planned to further investigate the impact of pre-injury
anti-platelet use on outcomes in blunt chest wall trauma patients.
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